Pancreatitis - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H1 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pancreatitis - Overview
Pancreatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pancreatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pancreatitis - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Atox Bio Ltd
Bharat Serums And Vaccines Ltd
CalciMedica Inc
Cypralis Ltd
Dynavax Technologies Corp
Generon (Shanghai) Corp Ltd
GlaxoSmithKline Plc
LipimetiX Development Inc
Novartis AG
Pharming Group NV
Sun BioPharma Inc
Pancreatitis - Drug Profiles
AB-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-4620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DV-1179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-180 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2795039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-6288B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-2pal18S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-20201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulinastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Withaferin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pancreatitis - Dormant Projects
Pancreatitis - Discontinued Products
Pancreatitis - Product Development Milestones
Featured News & Press Releases
Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis
Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Pancreatitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pancreatitis - Pipeline by Angion Biomedica Corp, H1 2017
Pancreatitis - Pipeline by Atox Bio Ltd, H1 2017
Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H1 2017
Pancreatitis - Pipeline by CalciMedica Inc, H1 2017
Pancreatitis - Pipeline by Cypralis Ltd, H1 2017
Pancreatitis - Pipeline by Dynavax Technologies Corp, H1 2017
Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
Pancreatitis - Pipeline by GlaxoSmithKline Plc, H1 2017
Pancreatitis - Pipeline by LipimetiX Development Inc, H1 2017
Pancreatitis - Pipeline by Novartis AG, H1 2017
Pancreatitis - Pipeline by Pharming Group NV, H1 2017
Pancreatitis - Pipeline by Sun BioPharma Inc, H1 2017
Pancreatitis - Dormant Projects, H1 2017
Pancreatitis - Discontinued Products, H1 2017